Next Article in Journal
Co-Expression of IL-7 Improves NKG2D-Based CAR T Cell Therapy on Prostate Cancer by Enhancing the Expansion and Inhibiting the Apoptosis and Exhaustion
Previous Article in Journal
Effectiveness and Safety of Nivolumab in Child–Pugh B Patients with Hepatocellular Carcinoma: A Real-World Cohort Study
Previous Article in Special Issue
TYK2 in Tumor Immunosurveillance
Editorial

JAK-STAT Signalling Pathway in Cancer

1
The University of Queensland Diamantina Institute, The University of Queensland, Translational Research Institute, Qld 4072, Australia
2
The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC 3052, Australia
*
Author to whom correspondence should be addressed.
Cancers 2020, 12(7), 1971; https://doi.org/10.3390/cancers12071971
Received: 16 July 2020 / Accepted: 17 July 2020 / Published: 20 July 2020
(This article belongs to the Special Issue JAK-STAT Signalling Pathway in Cancer)
No abstract available
View Full-Text
MDPI and ACS Style

Brooks, A.J.; Putoczki, T. JAK-STAT Signalling Pathway in Cancer. Cancers 2020, 12, 1971. https://doi.org/10.3390/cancers12071971

AMA Style

Brooks AJ, Putoczki T. JAK-STAT Signalling Pathway in Cancer. Cancers. 2020; 12(7):1971. https://doi.org/10.3390/cancers12071971

Chicago/Turabian Style

Brooks, Andrew J., and Tracy Putoczki. 2020. "JAK-STAT Signalling Pathway in Cancer" Cancers 12, no. 7: 1971. https://doi.org/10.3390/cancers12071971

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop